FDA Countdown Starts: New PTSD Drug For Anxiety Disorders

A pill that pairs an antipsychotic with a common antidepressant just cleared a major regulatory hurdle for treating post-traumatic stress disorder, and doctors, veterans, and skeptics are all watching to see if it lives up to the hope.

Quick Take

The Food and Drug Administration (FDA) accepted a filing for brexpiprazole combined with sertraline to treat adults with PTSD, setting a formal review deadline.
A phase 3 trial showed the combo beat sertraline alone on a standard PTSD symptom scale.
President Trump signed an executive order pushing faster reviews for PTSD treatments, including psychedelic drugs.
An FDA advisory panel already rejected one high-profile psychedelic PTSD treatment, MDMA, showing scrutiny hasn’t disappeared.
Only two drugs, sertraline and paroxetine, currently carry full FDA approval for PTSD, according to the American Psychological Association.

A Regulatory Green Light, Not Yet A Cure

Otsuka and Lundbeck announced the FDA accepted their supplemental application for brexpiprazole plus sertraline in adults with PTSD, setting a target decision date of February 8, 2025. Acceptance means the filing is complete enough for full review. It does not mean approval. That distinction matters, because PTSD patients have waited decades for a new option beyond the two drugs already on the market.

The American Psychological Association still lists sertraline and paroxetine as the only medications carrying full FDA approval specifically for PTSD. Everything else, including this new combination, remains under review or used off-label. That gap explains why any credible new candidate draws intense attention from clinicians, veterans’ groups, and investors watching the pharmaceutical pipeline closely.

The Trial Data Behind The Buzz

Medscape reported the phase 3 trial found the brexpiprazole-sertraline combination produced significantly greater symptom relief than sertraline plus placebo, measured on the Clinician-Administered PTSD Scale at week ten. Patients also reported functional improvement by week twelve. Those numbers are real and peer-reviewed. But they cover a short trial window, not years of use, and they haven’t yet cleared the FDA’s final approval bar.

A Cochrane review of PTSD drug treatments found moderate-certainty evidence that SSRIs like sertraline already help many patients, while several other drug classes tested over the years showed no benefit at all. That history matters here. It shows regulators have good reason to demand solid proof before adding a new medication to the short approved list, rather than rushing based on early enthusiasm alone.

Washington Adds Fuel To The Fire

President Trump signed an executive order in April directing federal health agencies to speed up access to treatments for serious mental illness, and the FDA responded by accelerating review timelines for several PTSD candidates, including psychedelic-adjacent compounds. Supporters call it overdue relief for veterans stuck with limited options. Faster review pathways speed up paperwork, not proof, and the underlying science still has to hold up.

One compound moving through this faster track, methylone, earned Breakthrough Therapy designation from the FDA after early positive results in its IMPACT-1 study. That designation signals promise, not a finished verdict. History shows some candidates that look strong early still stumble later when regulators scrutinize the full dataset under standard evidentiary rules.

Why Skeptics Say Slow Down

The clearest warning sign in this space came in 2024, when an FDA advisory committee unanimously voted against approving MDMA-assisted therapy for PTSD, citing safety and study-design concerns. That rejection proves the agency will say no to a psychedelic PTSD treatment even after years of hype and heavy advocacy. It’s a useful reminder that political momentum and patient testimonials don’t guarantee regulatory success.

An FDA advisory review of a related psychiatric drug program from July 2025 found one late-stage trial was robustly positive while a second trial in the same program showed essentially zero treatment effect. That kind of split result is common in psychiatric drug development. It’s exactly why conservative caution, checking full data sets rather than single headline trials, protects patients from false hope dressed up as breakthrough medicine.

What Veterans And Patients Should Watch Next

The real test comes when the FDA finishes its full review of the brexpiprazole-sertraline application and either approves or rejects it based on the complete trial record, not press releases. Veterans groups, doctors, and families dealing with PTSD deserve treatments proven safe and durable, not just statistically significant for a few weeks. Genuine progress matters, but so does getting the science right the first time.